Loading organizations...
Loading organizations...
Develops novel oral inhibitors for prostate and hormonally-driven cancers.
Innocrin Pharmaceuticals has raised $28.0M across 1 funding round.
Innocrin Pharmaceuticals has raised $28.0M in total across 1 funding round.
Innocrin Pharmaceuticals has raised $28.0M in total across 1 funding round.
Innocrin Pharmaceuticals's investors include Fred Eshelman, A&B Equity Holdings, Hatteras Venture Partners, Intersouth Partners, Lilly Ventures, Novartis.
Innocrin Pharmaceuticals has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series D in April 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 14, 2015 | $28.0M Series D | Fred Eshelman | A&B Equity Holdings, Hatteras Venture Partners, Intersouth Partners, Lilly Ventures, Novartis |